British drugmaker Vectura has signed an exclusive deal with Novartis unit Sandoz to develop a generic version of an existing major inhaled combination therapy for asthma and COPD in the US.
Read More
UK group Vectura saw its shares drop 10 percent after partner Munipharma reported that respiratory drug flutiform failed to hit targets in a late-stage trial involving patients with chronic obstructive pulmonary disease.
Read More
Skyepharma has bought itself access Lucideon’s abuse-deterrent drug delivery technology to use in the development of a new formulation of an undisclosed opioid.
Read More
